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Although prostate specific antigen (PSA) screening of asymptomatic 
men aged 50 - 75 years may reduce the prostate cancer mortality by at 
least 20%, there is concern about the high rate of overtreatment.1 The 
risk of overtreatment is increased in older men with less aggressive 
cancer. In men younger than 50 years – especially those with high-
risk prostate cancer – early diagnosis and curative treatment are more 
important than in elderly men, and the risk of overtreatment is less.
Before the advent of widespread PSA testing, men <50 years old 
comprised 0.8 - 1.1% of patients diagnosed with adenocarcinoma of 
the prostate in the USA.2 With the widespread use of PSA testing and 
public awareness of prostate cancer, this figure in the USA is currently 
3.7 - 4%.3
Pre-PSA era studies suggested that prostate cancer in younger 
men is more aggressive, presents at a more advanced stage, responds 
poorly to radiation or hormonal therapy, and has a worse prognosis 
than in older men.4 Other studies have suggested that younger 
men present with more favourable disease and have better survival 
outcomes than older men.5 Some reports suggested no significant 
difference in clinical stage at diagnosis or disease recurrence rates 
between younger and older men.6 Recent studies have shown that 
younger men in the PSA era have better outcomes than older men.3,5,7
We aimed to evaluate the presenting features and treatment 
outcome of prostate cancer in men aged <50 years, in a region where 
PSA screening is not available and most men present with symptoms.
Materials and methods
We analysed the data of 1 571 men diagnosed with adenocarcinoma 
of the prostate in the period January 1997 to December 2008 at our 
institution, a tertiary level public sector hospital serving a largely 
indigent population. The majority presented with symptoms, because 
PSA testing is not readily available at clinics or hospitals in our 
referral area. Because many studies suggest that prostate cancer is 
more common and more aggressive in Blacks, the study data were 
also analysed for patients’ race.
Histological grading was divided into well differentiated (MD 
Anderson grade 1, Gleason score 2 - 4), moderately differentiated 
(G2, Gleason 5 - 7) and poorly differentiated (G3, Gleason 8 - 10). 
Clinical tumour stage on digital rectal examination was categorised as 
organ-confined (T1 - 2) or locally advanced (T3 - 4). Haematogenous 
metastases were evaluated with X-rays of the axial skeleton and 
radionuclide scintigraphy in selected patients, and were categorised 
as absent (M0) or present (M1).
Statistical analysis was performed using Student’s t-test for 
parametric data, Mann-Whitney test for non-parametric data, and 
Fisher’s exact test for contingency tables. A two-tailed p-value 
<0.05 was accepted as statistically significant. Ethical approval was 
provided by the health research ethics committee of the University 
of Stellenbosch.
Results
Of the 1 571 men, 47 (3%) were aged ≤50 years. Race was self-
assigned as white in 27.3%, coloured in 65.1% , and black in 
7.7%. This racial distribution reflects our hospital patients’ 
population demographics. In the group of men <50 years old, 
the proportion of white men was significantly lower, and the 
proportion of coloured men was higher than in the age group 
>50 years (Fig. 1).
The proportion of high-grade tumors was significantly greater in 
the age group <50 years (53%) than in any of the other age groups 
(Fig. 2). The proportion of locally advanced (T3 - 4) tumours was 
significantly greater in the age group <50 years (56%) than in the 
age groups 51 - 60 and 61 - 70 years (42%), but smaller than in the 
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Objective. We aimed to evaluate the presenting features and 
treatment outcome of prostate cancer in men aged <50 years, in 
a region where prostate specific antigen (PSA) screening is not 
readily available and most men present with symptoms.
Methods. We analysed the data of 1 571 men with prostatic 
adenocarcinoma treated between January 1997 and December 2008 
at our institution, a tertiary level public sector hospital serving a 
largely indigent population. Statistical analysis was performed 
using Student’s, the Mann-Whitney and Fisher’s exact tests where 
appropriate (p<0.05 accepted as statistically significant).
Results. Of 1 571 men, 47 (3%) were aged <50 years. The 
group aged <50 years, compared with that aged >50 years, had 
a significantly greater proportion with poorly differentiated 
adenocarcinoma (53%), locally advanced (stage T3 - 4) tumours 
(56%), haematogenous metastases (75%), significantly higher 
serum PSA at diagnosis (mean 621, median 74 ng/ml) and shorter 
survival.
Conclusions. Men aged <50 years presenting with symptoms 
owing to prostate cancer had significantly higher-risk disease, 
higher mean PSA, and poorer prognosis than men aged >50 years. 
To diagnose prostate cancer at a potentially curable stage in men 
aged <50 years, it is necessary to initiate baseline PSA testing at age 
40 and 45 years, and to select high-risk men for PSA surveillance 
in order to diagnose potentially curable cancer in those with a life 
expectancy >20 - 25 years.
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age group 81 - 90 years (74%) (Fig. 3). The proportion of men with 
haematogenous metastases was significantly greater in the group 
aged <50 years (75%) than the other age groups (Fig. 3).
Mean and median serum PSA at diagnosis was significantly higher 
in the group aged <50 years than the other groups (Fig. 4). In the group 
<50 years old, 39% had a serum PSA <20 ng/ml, 22% had a PSA 21 - 
99 ng/ml, and 39% had a PSA >100 ng/ml at diagnosis, ranging from 
105.0 - 7 000.0 ng/ml. Five men had a PSA >1 000 ng/ml.
Potentially curative therapy (radical prostatectomy or radiotherapy) 
was used in a similar proportion of patients in the group aged <50 
years as in the groups aged 51 - 70 years (Fig. 5).
Mean and median follow-up (reflecting overall survival) was 
significantly shorter in the groups aged <50 and 81 - 90 years than in 
the other groups (Fig. 6).
Discussion
In this study of men with prostate cancer who were diagnosed 
because of symptomatic presentation and not through PSA screening 
of asymptomatic men, the proportion aged <50 years (3%) was higher 
than that reported in the USA during the pre-PSA era (0.8 - 1.1%), 
and lower than reported in the PSA era (3.7 - 4%). 3
The features of aggressive prostate cancer (high grade, advanced 
stage, high serum PSA) were significantly more common in men 
aged <50 years in our study population, which corresponds with 
studies from the USA in the pre-PSA era,4 but is contrary to 
studies reporting more favourable disease at presentation and better 
treatment outcomes in younger men.3,5,7 
Changes in PSA levels over time (PSA kinetics) can help to detect 
potentially fatal prostate cancer. Carter et al. (1992) first reported 
that a PSA velocity (PSAV) >0.75 ng/ml/year indicated an increased 
risk for the development of prostate cancer.8 Other studies have Fig. 1. Race distribution in various age groups. 
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Fig. 1. Race distribution in various age groups. 
Fig. 2. Histological grades in various age groups. 
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Fig. 2. Histological grades in various age groups.
Fig. 3. Clinical tumour stage in various age groups. 
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Fig. 3. Clinical tumour stage in various age groups.
Fig. 4. Mean and median serum PSA at presentation in various age groups. 
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Fig. 4. Mean and median serum PSA at presentation in various age groups.
Fig. 5. Initial treatment in various age groups.
Fig. 5. Initial treatment in various age groups. 
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Fig. 6. Duration of follow-up in various age groups. 
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shown that a PSAV >2 ng/ml/year, calculated by linear regression, 
was associated with an increased risk of death from prostate cancer.9
In men with untreated prostate cancer, PSA levels increase initially 
linearly, followed by an exponential phase.9 Therefore, PSA doubling 
time (PSADT) calculated using log-linear regression may be a more 
appropriate measure of cancer growth. A shorter PSADT is associated 
with a higher risk of death from prostate cancer.10
It has been suggested that a screening interval of 3 years is 
appropriate for men with a PSA <1 ng/ml, and that it seems safe to 
offer repeat PSA screening after 2 years for men with a PSA <2 ng/ml, 
since rapidly growing interval cancers appear to be rare.11 It has been 
suggested that men with a PSA of 2 - 3 ng/ml may be better served 
with a shorter screening interval.12
A computer model13 to simulate the natural history of prostate 
cancer to determine the optimal starting age for PSA testing showed 
that annual PSA testing from the age 50 years compared with no 
screening prevented 3.2 deaths, with an additional 10 500 PSA 
tests and 600 prostate biopsies. PSA testing at ages 40 and 45 years 
followed by biennial testing beginning at age 50 years prevented 3.3 
deaths, with an additional 7 500 PSA tests and 450 prostate biopsies. 
The authors concluded that screening men at age 40 and 45 years 
with a 2-year testing interval after age 50 years (or before if the PSA 
level >2.0 ng/ml), while holding the PSA threshold for a prostate 
biopsy at 4.0 ng/ml, may be more efficient than annual PSA screening 
from the ages of 50 - 75 years, because it could prevent an equal 
number of prostate cancer deaths and reduce the number of PSA tests 
administered and biopsies performed.13
Men with PSA levels >2.0 ng/ml are more than 12 times as likely to 
be diagnosed with prostate cancer within the next decade compared 
with those with PSA levels <1.0 ng/ml.14 These data support the 
rationale for increased surveillance of young men with normal PSA 
levels ≥2.0 ng/ml, while continuing to use 4.0 ng/ml as the cut-off for 
taking a biopsy.13
In our study of men <50 years who presented because of symptoms 
and were diagnosed with prostate cancer, 39% had a PSA >100 ng/
ml at diagnosis, ranging from 105.0 - 7 000.0 ng/ml. Postulating an 
exponential rather than linear PSA increase and a PSADT of <12 
months in these men presenting with PSA>100 at the age of 50 years, 
it is clear that to detect cancer at a potentially curable stage (PSA <20 
ng/ml) would have required PSA testing at the age of 40, or even 
earlier.
In a large cohort of men aged <50 years with a PSA <4 ng/ml at the 
first PSA screening, black and white men with an initial PSA in the 
1.5 - 2.4 ng/ml range had a 9.3- and 6.7-fold increase in the risk for 
prostate cancer, respectively. These data suggest that an initial PSA 
cutoff of 1.5 ng/ml may be better than a median PSA of 0.7 ng/ml to 
determine the risk of prostate cancer in men aged <50 years.15
An important problem in prostate cancer treatment was succinctly 
summarised in the question posed by W F Whitmore: ‘If cure is 
possible, is it necessary? And if it is necessary, is it possible?’16 Many 
prostate cancers are not aggressive and, even if untreated, will not 
cause the patient’s death. However, some prostate cancers are so 
aggressive that no combination of therapeutic modalities can effect 
cure. However, it is clear that early-stage cancer has a greater chance 
of cure than advanced cancer.16
Although PSA screening of asymptomatic men may reduce 
prostate cancer mortality, there is a high rate of overtreatment, 
especially in older men.1 As a public health measure, PSA screening 
is most probably not cost-effective, especially because prostate cancer 
mainly affects older men who are not economically productive.17 
Nevertheless, from the individual’s point of view, it is preferable to 
diagnose and treat prostate cancer at a potentially curable stage, 
rather than suffer the extreme pain of skeletal metastases in terminal 
prostate cancer.
Conclusions
In our referral population, where PSA testing is not readily available 
and most men present with symptoms, 3% of patients diagnosed 
were aged <50 years. Of them, a significantly greater proportion 
had high-grade adenocarcinoma, locally advanced or metastatic 
disease, serum PSA >100 ng/ml, and shorter overall survival follow-
up compared with those >50 years old. To diagnose prostate cancer 
at a potentially curable stage in men <50 years old, initial baseline 
PSA testing must be extended to the age range 40 - 45 years, to select 
men at increased risk of cancer (PSA >0.7 - 1.5 ng/ml). Annual PSA 
surveillance should be targeted at these high-risk men, with the aim 
of diagnosing prostate cancer at a potentially curable stage in men 
with life expectancy >20 - 25 years. In men at low risk of developing 
prostate cancer, PSA testing can be deferred to the age of 50 and can 
be performed at less frequent intervals (3 - 4 times yearly); this may 
be a more cost-effective way of detecting aggressive prostate cancer 
at a curable stage.
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